About Mitsubishi tanabe pharma development america
Mitsubishi Tanabe Pharma Development America: Innovating for a Healthier Future
Mitsubishi Tanabe Pharma Development America is a subsidiary of Mitsubishi Tanabe Pharma Corporation, a global pharmaceutical company that has been at the forefront of medical innovation for over 300 years. The company's mission is to develop and deliver innovative therapies that address unmet medical needs and improve the lives of patients around the world.
With its headquarters in Jersey City, New Jersey, Mitsubishi Tanabe Pharma Development America focuses on developing new treatments for neurological disorders, autoimmune diseases, and rare diseases. The company's research and development efforts are guided by a deep commitment to scientific excellence and patient-centered care.
In this article, we will explore the history of Mitsubishi Tanabe Pharma Development America, its current research initiatives, and its vision for the future.
History
Mitsubishi Tanabe Pharma Corporation was founded in 1678 as a traditional Japanese medicine shop called "Tanabe-ya." Over time, it evolved into a modern pharmaceutical company with a global presence. In 2008, Mitsubishi Chemical Holdings Corporation acquired all outstanding shares of Tanabe Seiyaku Co., Ltd., which became Mitsubishi Tanabe Pharma Corporation.
In 2015, Mitsubishi Tanabe Pharma Corporation established its U.S.-based subsidiary: Mitsubishi Tanabe Pharma Development America (MTDA). MTDA was created to accelerate drug development activities in North America by leveraging local expertise in clinical development operations.
Research Initiatives
MTDA is focused on developing innovative therapies that address unmet medical needs across several therapeutic areas. One area of focus is neurological disorders such as amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), multiple sclerosis (MS), spinal muscular atrophy (SMA) among others. These conditions can be debilitating or even fatal if left untreated or poorly managed.
MTDA has several ongoing clinical trials aimed at developing new treatments for these conditions. For example:
- Edaravone: MTDA developed edaravone as an intravenous treatment option for ALS patients who have rapidly progressing symptoms.
- Atogepant: MTDA developed atogepant as an oral medication designed to prevent migraines.
- Tirasemtiv: MTDA developed tirasemtiv as an oral medication designed to improve muscle function in ALS patients.
- RAD001/everolimus: MTDA conducted clinical trials evaluating everolimus' efficacy against tuberous sclerosis complex-associated seizures.
These are just some examples from their extensive portfolio; they have many other projects underway across various therapeutic areas including oncology & immunology among others.
Vision
The ultimate goal of MTDA is to help people enjoy healthier lives through innovative therapies that address unmet medical needs. To achieve this goal they are committed to:
1) Developing novel therapeutics - They aim to develop novel therapeutics with unique mechanisms-of-action that can provide significant benefits over existing treatments or fill gaps where no effective therapy exists today.
2) Patient-centric approach - They believe it’s important not only focus on treating diseases but also improving quality-of-life outcomes such as reducing symptom burden or improving functional status so patients can live more fulfilling lives despite their condition(s).
3) Collaborations - They collaborate with academic institutions & other industry partners worldwide who share similar goals so they can leverage each other’s strengths & expertise towards common objectives.
Conclusion
Mitsubishi Tanabe Pharma Development America has built upon centuries-old legacy by continuing their tradition of innovation through cutting-edge research initiatives aimed at addressing unmet medical needs across various therapeutic areas including neurology & rare diseases among others. Their commitment towards patient-centric approach combined with collaborations makes them one of the leading companies working towards making healthcare better globally!
mt-pharma-development-america.com
